Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus

详细信息    查看全文

• 作者：Man Wang ; Shuai Jiang ; Zhenwei Han ; Bing Zhao…
• 关键词：EBV ; Recombinant gp350 ; Pichia pastoris ; Immunogenicity ; Subunit vaccine
• 刊名：Applied Microbiology and Biotechnology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：100
• 期：3
• 页码：1221-1230
• 全文大小：1,765 KB
• 参考文献：Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J (2006) Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203(4):995–1006PubMed PubMedCentral CrossRef
  Ahmad M, Hirz M, Pichler H, Schwab H (2014) Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol 98(12):5301–5317PubMed PubMedCentral CrossRef
  An N, Ou J, Jiang D, Zhang L, Liu J, Fu K, Dai Y, Yang D (2013) Expression of a functional recombinant human basic fibroblast growth factor from transgenic rice seeds. Int J Mol Sci 14(2):3556–3567PubMed PubMedCentral CrossRef
  Balfour HH Jr (2014) Progress, prospects, and problems in Epstein-Barr virus vaccine development. Curr Opin Virol 6:1–5PubMed CrossRef
  Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13(5):577–585PubMed CrossRef
  Cardoso SA, Paixao VF, Oliveira MD, Honda ER, Oliveira LL, da Silva CC, De Paula SO (2013) Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis. Protein Expr Purif 92(1):9–13PubMed CrossRef
  Cohen JI (2015) Epstein-Barr virus vaccines. Clin Transl Immunol 4(1):e32CrossRef
  Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011) Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3(107):107fs7PubMed PubMedCentral CrossRef
  Cohen JI, Mocarski ES, Raab-Traub N, Corey L, Nabel GJ (2013) The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31(Suppl 2):B194–B196PubMed PubMedCentral CrossRef
  Conway M, Morgan A, Mackett M (1989) Expression of Epstein-Barr virus membrane antigen gp340/220 in mouse fibroblasts using a bovine papillomavirus vector. J Gen Virol 70(Pt 3):729–734PubMed CrossRef
  Cregg JM, Tolstorukov I, Kusari A, Sunga J, Madden K, Chappell T (2009) Expression in the yeast Pichia pastoris. Methods Enzymol 463:169–189PubMed CrossRef
  Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT, Snapper DM, Snow AL, Mond JJ, Snapper CM (2013) A novel tetrameric gp3501-470 as a potential Epstein-Barr virus vaccine. Vaccine 31(30):3039–3045PubMed PubMedCentral CrossRef
  Damasceno LM, Huang CJ, Batt CA (2012) Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol 93(1):31–39PubMed CrossRef
  Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55(9):1228–1235PubMed PubMedCentral CrossRef
  Demain AL, Vaishnav P (2009) Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 27(3):297–306PubMed CrossRef
  Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ (1992) Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol 73(Pt 2):449–453PubMed CrossRef
  Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ (1994) Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12(13):1180–1184PubMed CrossRef
  Green M, Michaels MG (2013) Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13(Suppl 3):41–54, quiz 54 PubMed CrossRef
  Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171–177PubMed
  Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, Park CG, Steinman RM, Munz C (2008) Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112(4):1231–1239PubMed PubMedCentral CrossRef
  Han X, Ye LB, Li BZ, Bo G, Cai WJ, Hong Z, She YL, Li Y, Kong LB, Wu ZH (2006) Expression, purification and characterization of the hepatitis B virus entire envelope large protein in Pichia pastoris. Protein Expr Purif 49(2):168–175PubMed CrossRef
  Hardy E, Martinez E, Diago D, Diaz R, Gonzalez D, Herrera L (2000) Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J Biotechnol 77(2–3):157–167PubMed CrossRef
  Hawkins JB, Delgado-Eckert E, Thorley-Lawson DA, Shapiro M (2013) The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation. PLoS Pathog 9(10):e1003685PubMed PubMedCentral CrossRef
  Jackman WT, Mann KA, Hoffmann HJ, Spaete RR (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17(7–8):660–668PubMed CrossRef
  Jung S, Chung YK, Chang SH, Kim J, Kim HR, Jang HS, Lee JC, Chung GH, Jang YS (2001) DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. Mol Cells 12(1):41–49PubMed
  Kato K, Sano H, Nagata K, Sugihara H, Kanai K, Kuwamoto S, Kato M, Murakami I, Hayashi K (2012) Synthetic peptides of Epstein-Barr virus-major envelope glycoprotein-350/220 do not prevent infection in a rabbit Epstein-Barr virus infection model. J Vaccines Vaccin 3:148CrossRef
  Kim T, Mullaney EJ, Porres JM, Roneker KR, Crowe S, Rice S, Ko T, Ullah AH, Daly CB, Welch R, Lei XG (2006) Shifting the pH profile of Aspergillus niger PhyA phytase to match the stomach pH enhances its effectiveness as an animal feed additive. Appl Environ Microbiol 72(6):4397–4403PubMed PubMedCentral CrossRef
  Lu L, Wang TN, Xu TF, Wang JY, Wang CL, Zhao M (2013) Cloning and expression of thermo-alkali-stable laccase of Bacillus licheniformis in Pichia pastoris and its characterization. Bioresour Technol 134:81–86PubMed CrossRef
  Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, Silva AD, Swaminathan S, Khanna N (2013) Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. PLoS ONE 8(5):e64595PubMed PubMedCentral CrossRef
  Mok H, Cheng X, Xu Q, Zengel JR, Parhy B, Zhao J, Wang CK, Jin H (2012) Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol J 6:12–22PubMed PubMedCentral CrossRef
  Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M (2007) Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25(24):4697–4705PubMed CrossRef
  Nemerow GR, Mullen JJ 3rd, Dickson PW, Cooper NR (1990) Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J Virol 64(3):1348–1352PubMed PubMedCentral
  Nuebling CM, Buck M, Boos H, von Deimling A, Mueller-Lantzsch N (1992) Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells. Virology 191(1):443–447PubMed CrossRef
  Ogembo JG, Muraswki MR, McGinnes LW, Parcharidou A, Sutiwisesak R, Tison T, Avendano J, Agnani D, Finberg RW, Morrison TG, Fingeroth JD (2015) A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 13:50PubMed PubMedCentral CrossRef
  Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ (1993) Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 74(Pt 3):501–507PubMed CrossRef
  Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM (2009) A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88(8):1025–1029PubMed CrossRef
  Rickinson AB (2014) Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 26:99–115PubMed CrossRef
  Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI (2011) Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog 7(10):e1002308PubMed PubMedCentral CrossRef
  Shannon-Lowe C, Rowe M (2014) Epstein Barr virus entry; kissing and conjugation. Curr Opin Virol 4:78–84PubMed CrossRef
  Sitompul LS, Widodo N, Djati MS, Utomo DH (2012) Epitope mapping of gp350/220 conserved domain of Epstein Barr virus to develop nasopharyngeal carcinoma (NPC) vaccine. Bioinformation 8(10):479–482PubMed PubMedCentral CrossRef
  Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749–1753PubMed CrossRef
  Stewart JP, Micali N, Usherwood EJ, Bonina L, Nash AA (1999) Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Vaccine 17(2):152–157PubMed CrossRef
  Subathra M, Santhakumar P, Satyam Naidu S, Lakshmi Narasu M, Senthilkumar TM, Lal SK (2014) Expression of avian influenza virus (H5N1) hemagglutinin and matrix protein 1 in Pichia pastoris and evaluation of their immunogenicity in mice. Appl Biochem Biotechnol 172(7):3635–3645PubMed CrossRef
  Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS (2006) Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13(11):996–1001PubMed CrossRef
  Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM (2014) A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20(19):5009–5022PubMed PubMedCentral CrossRef
  Teng D, Fan Y, Yang YL, Tian ZG, Luo J, Wang JH (2007) Codon optimization of Bacillus licheniformis β-1,3-1,4-glucanase gene and its expression in Pichia pastoris. Appl Microbiol Biotechnol 74(5):1074–1083PubMed CrossRef
  Tse E, Kwong YL (2015) Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med 47:e136PubMed PubMedCentral CrossRef
  Wang M, Jiang S, Liu X, Wang Y (2013) Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris. Appl Microbiol Biotechnol 97(14):6251–6262PubMed CrossRef
  Wang JR, Li YY, Liu DN, Liu JS, Li P, Chen LZ, Xu SD (2015) Codon optimization significantly improves the expression level of α-amylase gene from Bacillus licheniformis in Pichia pastoris. Biomed Res Int 2015:248680PubMed PubMedCentral
  Whang Y, Silberklang M, Morgan A, Munshi S, Lenny AB, Ellis RW, Kieff E (1987) Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells. J Virol 61(6):1796–1807PubMed PubMedCentral
  Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP (2008) Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 82(22):11217–11227PubMed PubMedCentral CrossRef
  Yu P, Yan Y, Gu Q, Wang X (2013) Codon optimisation improves the expression of Trichoderma viride sp. endochitinase in Pichia pastoris. Sci Rep 3:3043PubMed PubMedCentral
  
• 作者单位：Man Wang (1)
  Shuai Jiang (2)
  Zhenwei Han (2)
  Bing Zhao (1)
  Li’ao Wang (1)
  Zhixia Zhou (1)
  Yefu Wang (2)
  
  1. Institute for Translational Medicine, Medical College of Qingdao University, Qingdao, 266021, China
  2. State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China
  
• 刊物类别：Chemistry and Materials Science
• 刊物主题：Chemistry
  Biotechnology
  Microbiology
  Microbial Genetics and Genomics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0614

文摘

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that is linked to the development of various malignancies. There is an urgent need for effective vaccines against EBV. EBV envelope glycoprotein gp350 is an attractive candidate for a prophylactic vaccine. This study was undertaken to produce the truncated (codons 1-443) gp350 protein (gp3501-443) in Pichia pastoris and evaluate its immunogenicity. The gp3501-443 protein was expressed as a secretory protein with an N-terminal His-tag in P. pastoris and purified through Ni-NTA chromatography. Immunization with the recombinant gp3501-443 could elicit high levels of gp3501-443-specific antibodies in mice. Moreover, gp3501-443-immunized mice developed strong lymphoproliferative and Th1/Th2 cytokine responses. Furthermore, the recombinant gp3501-443 could stimulate CD4+ and CD8+ T cell responses in vaccinated mice. Collectively, these findings demonstrated that the yeast-expressed gp3501-443 retained strong immunogenicity. This study will provide a useful source for developing EBV subunit vaccine candidates.